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Discussion and Summary Remarks*
Bloassays for Carcinogenicity
Much ofthis conference has concerned itselfwith
asinglechemical, di(2-ethylhexyl)phthalate(DEHP).
The National Cancer Institute (NCI)/National Tox-
icology Program (NTP) Bioassay Program, howev-
er, has tested a total of five phthalate esters or
relatedcompoundsforcarcinogenicpotential. These
are reviewed briefly below.
Phthalamide
Phthalamide (NCI TR-161) was found to be of
low acute toxicity, allowing it to be tested in mice
and rats at doses ofup to 3% (byweight) inthe diet.
Toxic lesions were produced in the livers and uri-
nary tracts of both species, but there was no evi-
dence that phthalamide was carcinogenic. Consid-
erablenumbersofanimalswerediagnosed ashaving
hyperplasia of the urinary bladder, and two of the
high-dose female rats had transitional cell carcino-
mas of the urinary bladder. The report mentions
excess calculus formation in the urine, but it is not
clearwhetherthatrepresentsprecipitated test sub-
stance, mineral deposit, or inflammatory exudate
that may have been inspissated. Hyperplasia ofthe
bladder mucosa may have been related to the pres-
ence offoreign material. On the other hand, it may
also have represented focal hyperplasia with dys-
plasia related to compound administration. A pos-
sible limitation in this report is that the control
groups are rather small with only 20 animals per
group. The test would have been more sensitive
with larger control groups. Testicular atrophy can-
not be adequately assessed in chronic studies with
the Fischer 344 rat because this strain develops a
virtually 100% incidence of interstitial cell tumors
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in the second year oflife, accompanied by germinal
cell atrophy. Testicular effects could be addressed
with early sacrifices or, better yet, with a different
strain of rats.
Phthalic Anhydride
Phthalic anhydride (NCI TR-159) was adminis-
tered in the diet at doses ofup to 5%, and even this
level did not appear to be a maximum tolerated
dose in the female rats. The test diets were formu-
lated everyone orone-and-a-halfweeks, eventhough
as much as 25% ofthe test compound was shown to
decompose upon storage for 10 days. The exact
doses administered, therefore, are unknown. The
only possible evidence for carcinogenicity from
phthalic anhydride in this bioassay was the occur-
rence of excess leukemia in the female rats in the
low-dose group. This was interpreted bythe authors
as not being significant because an excess ofleuke-
mia was not found in the corresponding high-dose
group. It should be noted, however, that of all the
possible cancer end points in the Fischer 344 rat,
leukemia is the most variable both in incidence and
in time to onset. Additional experimentation with
larger groups ofanimals may be required to evalu-
ate the possible leukemogenicity of phthalic anhy-
dride.
Di(2-ethylhexyl) Phthalate
The report on di(2-ethylhexyl) phthalate (DEHP)
has already been reviewed in this conference at
some length. Anunanswered question in this bioas-
say is whetherpalatability ortoxicity was the cause
of decreased weight gains. Interstitial cell tumors
ofthe testis in male rats were decreased in animals
administered the higher dose ofDEHP. In contrast
to the control group, which had 96% testicular
tumors, those administered the high dose ofDEHP
had only 23% testicular tumors. The rats adminis-
tered the high dose weighed less and may have had
alowertumorbackgroundincidencerelatedtobody
weight. It is more likely, however, that DEHP had
an inhibitory effect on testicular tumor formation,150
and this finding deserves further study. The weight
ofthe evidence for the carcinogenicity of DEHP is
very strong. The excess of liver tumors in both
sexes ofboth species in adose-related manner, with
supportingdatafrominvitrotransformation exper-
iments, is conclusive.
Di(2-ethylhexyl) Adipate
The bioassay report on di(2-ethylhexyl) adipate
(DEHA) indicated that the test chemical produced
liver tumors in female mice and possibly in male
mice. Not emphasized in the report were early
deaths in male mice administered the low dose of
the test substance. In the first year of the experi-
ment 22% ofthis group of animals died from unex-
plained causes, thus limiting the number ofanimals
at risk to late developing tumors. Liver tumors
were found as early as 37weeks afterthebeginning
oftestcompoundadministration, however, suggest-
ing that further evaluation, including age adjusted
analyses, may make it possible to reach a more
definitive conclusion.
Butyl Benzyl Phthalate
The fifth bioassay conducted by the NCI/NTP
was that of butyl benzyl phthalate. The authors of
this report concluded that butyl benzyl phthalate
may have produced leukemias infemale Fischer 344
rats, astheyoccurred morefrequently inthetreated
animals than in controls. The tumors were of the
myelomonocytic type commonlyfoundinthe Fischer
rat, however, and the background incidence ofthis
tumor type in Fischer rats has been found to be
variable. Another experiment, with larger groups
ofanimals, may indicate whether or not butyl ben-
zyl phthalate is capable of producing leukemia in
the female Fischer 344 rat. Both testicular and
thymic atrophy were reported in butyl benzyl
phthalate-treated rats. Testicular atrophy second-
arytophthalate esteradministration haspreviously
been noted, but the finding ofthymic atrophy indi-
cates that immunotoxicological studies should also
be considered. The NTP has indicated that the
apparent hemorrhage-induced deaths produced in
male rats bybutylbenzylphthalate will be explored
in another chronic study, with attention given to
both disorders of the clotting mechanism of the
blood vessels as well as to carcinogenic potential.
Critique
The NCI/NTP Bioassay Program, including the
testing ofphthalate esters and related compounds,
has proved invaluable in identifying chemicals with
carcinogenic potential. Review of the technical
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reports, however (many ofwhich were, admittedly,
only in draft form), indicates that improvement
could be made in their contents. More specifically,
tabular data need to be rigorously checked for
accuracy, experimentalfindingsshouldbedescribed
more completely and the discussion sections ought
to be expanded greatly to provide readers with a
wider perspective on the chemical under test and
explanations for the effects produced.
The descriptive studies of the NCI/NTP have
identified a potential problem, the carcinogenicity
ofphthalate esters. Chronic bioassays, however, do
not elucidate the molecular mechanisms oftoxicity
that are needed to provide credible bases for esti-
matinghumanrisk. Futurestudies, therefore, should
be directed towards the mechanistic aspects ofthe
biological effects of DEHP. A determination of
whetherDEHPexertsanygenotoxiceffectordirectly
damagesDNAisalogicalstartingpoint. Thisappears
to be an important issue in relation to contradictory
results which were obtained in short-term tests in
bacteria. It would be very useful to know whether
these agents bind covalently to DNA (and, if so,
what kind of binding occurs), and whether the
radioactivity incorporated into DNA depends upon
metabolic activation. This is important not only in
the understanding ofhowthese agents may act, but
also in interpreting results from the various short-
term tests. The simple addition of various types of
short-term tests to a study does not necessarily
improve the quality ofthe datathatis obtained, nor
does it help greatly in interpreting the possible risk
of the agent, especially if the series of short-term
tests is based upon the same end point. Thus, there
is a risk that by adding a lot of information on
short-term tests without having parallel studies on
the mechanism of action, more confusion than help
will be created. A balance between the two ap-
proaches appears to be essential.
In vitro cell transformation, on the other hand,
may or may not be the result of a DNA damaging
event. Itwouldbeinterestingtodeterminewhether
celltransformationincultureisparalleledbyincreased
peroxisome proliferation with this type ofagent or
with the hypolipidemic drugs. Many carcinogens
induce DNA damage and this damage has been
causallyassociated withcarcinogenesis. Atthesame
time, however, it should be noted that some carcin-
ogens do not necessarily act through this mecha-
nism. For example, diethylstilbestrol (DES) is car-
cinogenic in humans and causes celltransformation,
but there is only veryweakevidence thatitbinds to
DNA, and it is not mutagenic (1, 2). Another exam-
ple is TCDD, which has been examined for its
capacity to bind to DNA by Poland and Glover (3),
who showed that none existed. Yet this chemical
was a hepatocarcinogen for rats. From the publicDISCUSSION AND SUMMARY
health point of view, this type of agent which
induces tumors apparently through a mechanism
not involving DNA damage should not be consid-
ered less dangerous than DNA damaging agents.
Despite these potential problems in the interpre-
tation of mechanistic studies, it is generally felt
that such information can provide a more techni-
cally sound and scientifically relevant basis for risk
assessment than the purely descriptive studies.
The bioassay studies, therefore, can be viewed as
providing clues to the understanding of the toxic
potential of chronic exposure to phthalate esters.
The technical difficulties and high costs involved
in mechanistic studies preclude the performance
and duplication of each and every possible experi-
ment. It is apparent fromthis conference, however,
that several investigative groups throughout the
world are currently engaged in the safety evalua-
tion of phthalate esters. Every attempt should be
make to keep all ofthese groups in close communi-
cation regarding the outcomes of the experimental
work.*
Short-Term Tests and Their
Role in Assessing the Toxic
Potential of Phthalate Esters
The Chemical Manufacturers Association (CMA)
has proposed a battery of short-term tests to be
usedindeterminingwhichadditionalphthalate esters
ought to be tested for carcinogenicity, and the NTP
has outlined a program in progress concerning
short-term testing of these compounds. If short-
term tests are to be used as predictors of carcino-
genicity, then those to be considered should be
point mutations in mammalian cells, point muta-
tions in microbial cells, and in vitro transformation.
This was the grouping of tests suggested by the
Interagency Testing Committee some two years
ago. Unscheduled DNA synthesis in mammalian
cells can be used as an augmenting or supporting
assay. However, results from this test system are
dependent upon biological effects such as mutation
or in vitro transformation for interpretation. If
short-term tests are to be used to detect mutagenic
potential leading to an evaluation of genetic risk,
then chromosomal-level assays, such as in vivo and
*In response to this need, the National Toxicology Program
(NTP) and the United States Environmental Protection Agency
(EPA) have organized a clearinghouse for collection and dis-
semination of information on phthalates. Contact: Ms. Joan
Chase, International Clearinghouse onPhthalate Esters, National
Toxicology Program, Landow Building, NIH, Bethesda, Md.
20205.
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in vitro cytogenetics analysis, would have to be
included.
Positive results in the first grouping of assays
would suggest a need to assess carcinogenicity in
rodents, while positive results in the second group-
ing would suggest a need to measure germ cell
effects in animals. The major application of short-
term tests identified by this conference is predic-
tion ofcarcinogenic potential. At the present time,
published resultsofshort-tern testsdonotgenerally
indicate that DEHP is genotoxic. However, test
results on the monoester and the ethylhexyl alcohol
are suggestive of such, though not confirmed, and
the suggestion is that these components may be
mutagenic. Reproducible results in different labo-
ratories are needed to confirmthese initial findings.
It is essential that this scientific process be satisfied
before labels of genotoxicity or lack thereof are
applied.
Attention should be paid in the short-term tests
tothe metabolic activation systemsused. Foralmost
all classes of chemicals requiring metabolic activa-
tion, this is probably the most critical element in
this type of assay. There are various types of
metabolic activation systems (e.g., freshly isolated
liver cells) which are used in addition to an S9
fraction. The metabolism of DEHP in most short-
term test systems is unknown. At a minimum,
therefore, the diester, the monoester and the al-
cohol-i.e., DEHP, mono(2-ethylhexyl) phthalate
and 2-ethylhexanol-should be subjected to the
short-term tests. The activities of other, lesser
metabolites existing in higher oxidized states may
have to be evaluated on a case-by-case basis.
By using in vivo systems, where possible, the
entire spectrum of metabolites can be assessed.
This brings to consideration other models for eval-
uating the phthalates. One assay which permits the
metabolicactivityofthewholeanimaltobeexpressed
is the testing of urine from chemically treated ani-
mals on microbial or mammalian indicator cells. If
positive, this model, coupled with appropriate ana-
lyticaltechniques, could identify the active metabo-
lites. Another whole animal model which could be
considered is invivo cytogenetics. Itmaybe argued
that this assay is insensitive. However, it may give
a truer reflection of any perceived hazard at a rea-
sonable dose level. Further, and just as important,
there appears to be a strong correlation between
chemicals which are positive in mammalian germ
cells -inotherwords, producingchromosomallevel
effects-and those which are also positive in in
vivo cytogenetic assays (e.g., bone marrow cells
using metaphase analysis). This is an important
aspect of genetic toxicology testing which has not
been fully appreciated to date. It is suggested,
therefore, that compounds be tested in this model152
as a means of selection for dominant lethal or heri-
table translocation assays. Additional consideration
should be given to in vivolin vitro testing. Methods
are available to expose liver cells in vivo, remove
them and measure -unscheduled DNA synthesis in
vitro. This would focus, in vivo, on the liver, the
organ of most concern in the carcinogenesis bioas-
say of DEHP.
Finally, a note should be made on the data indi-
catingevidenceofdominantlethaleffectsofphthalate
esters in rodents. Evaluation ofthese experiments
are complicated by the use ofextremely large, toxic
doses andinadequatenumbers offemales andtreated
male animals. Many of the phthalate esters are
known to damage the seminiferous tubular epithe-
lium of the testes. Moreover, the end point in this
test-fetal wastage-could result from a direct
toxic, nongenetic effect on the germinal cells. The
dominant lethal studies bear repeating, therefore,
with the inclusion ofdoses that are not toxic to the
testis.
Review of CMA and NTP Testing
Programs
The testing program of the CMA (4) is designed
toindicate whetheradditionalphthalate estersneed
to undergo carcinogenicity testingin animals, while
that ofthe NTP (5) is directed more to determining
the mechanism of DEHP carcinogenicity and to
evaluatingthe othertoxiceffectsofphthalate esters.
The complementary nature of these two programs
is purposeful, rather than coincidental, reflecting a
determined effort on the part of both government
and industry to avoid costly duplication of effort.
Some ofthe less obvious points ofthese programs
should be noted. First, ifthe carcinogenic potential
ofphthalate esters is being questioned on the basis
of the DEHP chronic bioassay results, then the
short-term tests utilized to prioritize such agents
for carcinogenicity testing ought to be those in
which DEHP is active. To date there is no concensus
as to whether or not DEHP is active (positive) in
short-term tests. The CMA and NTP programs
wisely propose, therefore, that any battery of short-
term tests used to identify phthalate esters for
testing in abioassay include tests inwhich DEHPis
active.
Secondly, chemicals can cause cancer via nonge-
netic mechanisms, a likely one for DEHP (based on
biological effects) is promotion. The NTP program,
therefore, includes the testing of DEHP for liver
tumor promotional activity. It must be recognized,
however, that there is no single, standard test for
liver tumor promoters nor is there any definitive
indication ofthe mechanism of tumor promotion in
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the experimental systems currently available. The
results of the DEHP promoter studies, therefore,
no matter how well conducted, are likely to be
confusingandcontroversial. Nonetheless, theirper-
formance may suggest a mechanism of DEHP car-
cinogenicity.
In addition to the CMA and NTP programs, two
groups have indicated that they are currently eval-
uating the abilities of DEHP, mono(2-ethylhexyl)
phthalate and 2-ethylhexanol to bind to liver DNA.
These studies are most important not only because
they may suggest a mechanism of DEHP carcino-
genicity, but because they could indicate which
metabolites of DEHP are causative of cancer and
whether or not species differences in the metabo-
lism of mono(2-ethylhexyl) phthalate preclude the
use ofrodents as valid models ofhuman response to
DEHP.
Finally, mention has been made of possible epi-
demiologicalstudiesofphthalateestertoxicity. While
recognizing that negative epidemiological studies
are often inconclusive, it is still felt that an attempt
should be made to identify persons with high expo-
sures to phthalate esters and to determine whether
their health status has been compromised. Medical
patients exposed to DEHP via repeated transfu-
sions or hemodialysis are probably not an accept-
able group because ofntumerous confounding health
problems. Both cancer and infertility should be
considered in any epidemiological evaluation.
Summary Remarks
It is clear from the data presented at this confer-
ence and the resulting discussion that the evalua-
tion of chemical safety is a very complex issue. In
addition to the science involved, regulatory deci-
sions must take into account economic impacts,
technical capabilities and comparative toxicities of
substitutes when the safety of a chemical or a
process is questioned. This conference may not
simplify the decision-making burden in the case of
plasticizers, but public presentation and discussion
ofthe relevant information at least assures that the
scientificaspectsoftheproblemhavebeenidentified.
The carcinogenesis bioassay ofDEHP conducted
bythe NCI/NTP has been discussed previouslyin a
public forum and was reviewed and approved by a
peerreviewgroupofindependentscientists.*Clear-
ly, DEHP is carcinogenic to rodents. It is recog-
nized, however, that the evaluation of the risk to
*Meetingofthe National ToxicologyProgram Board ofScientific
Counselors' Technical Report SubcommitteeandPanelofExperts,
Conference Room 6, Building 31C, National Institutes ofHealth,
Bethesda, Md., October 15, 1980.DISCUSSION AND SUMMARY 153
man from exposure to phthalate esters involves
more than just a descriptive bioassay. Hence, the
needforprogramsconcerningmechanisms ofaction,
pharmacokinetics, interspecies comparisons and epi-
demiology as discussed at this conference. These
efforts are justified, particularly in the case of a
chemical which is so widely used and for which
there would appear to be no obvious safe substi-
tute.
Thelimitedresources availableforchemicalsafety
testing necessitate a mechanism for prioritizing
phthalate esters for chronic toxicity studies. Short-
term tests may be helpful in this function, but their
apparent inability to clearly identify DEHP as a
potentialcarcinogen, withtheexceptionoftherecent
Japanese studies, is troublesome. It may become
necessary to use a different strategy to determine
which phthalate esters are in need of assay for
carcinogenic potential. The point has been raised at
this conference of the need to determine whether
DEHP caused tumors in rats and mice by a genetic
or a nongenetic mechanism. This information would
behelpfulinunderstandingthetoxicology ofDEHP
and in interpreting short-term test results, but the
relative safeties of nongenotoxic carcinogens (such
as promoters) in comparison to genotoxic carcino-
gens is not well understood. Simple labeling of
chemicals as genotoxic or nongenetic carcinogens,
therefore, is not sufficient for safety evaluation.
The emphasis at this conference has clearly been
on the carcinogenic potential of phthalate esters.
Othertoxiceffects, such asteratogenicityandinfer-
tility, however, should not be ignored in assessing
the risk ofhuman exposures to plasticizers. Groups
such as the NTP have recognized the importance of
nontumor toxic effects and increasingly are incor-
porating more diverse experimental protocols into
their toxicological analyses. Too often the lack of
studies designed to evaluate toxicity have been
misinterpreted as a demonstrated lack of toxicity
and we must be careful not to repeat such errors,
particularly when comparing potential substitutes
for phthalate esters.
It is interesting to note that in 1972 the National
Institute of Environmental Health Sciences spon-
sored a Conference on Phthalic Acid Esters (6).
Although carcinogenic effects were not a major
issue at that time, it was felt nevertheless that the
high volume of production of these chemicals and
the large number ofpeople exposed to them neces-
sitated a clear understanding of their toxic poten-
tials. We still find ourselves in that situation, need-
ing more information, but with a better idea of
what we are seeking. Additionally, the spirit of
cooperation shown at this conference between gov-
ernment, industrial and independent scientists sug-
gests that we will reach that goal with all due
speed.
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